科学图书馆
-
Longitudinal Change in Galectin-3 and Incident Cardiovascular OutcomesA Ghorbani, V Bhambhani, RH Christenson et al. -
Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rateSardu C, Paolisso P, Sacra C et al.
-
Lifestyle Modifications for Preventing and Treating Heart FailureM Aggarwal, B Bozkurt, on behalf of American College of Cardiology’s Nutrition and Lifestyle Committee of the Prevention of Cardiovascular Disease Council.
-
Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart FailureDB Mark, PA Cowper, KJ Anstrom et al.
-
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-ReducedF Zannad, JP Ferreira, SJ Pocock et al.
-
The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failureS He, J Wu, RK Li et al.
-
The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5)P Joseph, K Swedberg, DP Leong et al.
-
Dapagliflozin for treating chronic heart failure with reduced ejection fractionNational Institue for Health and Care Excellence
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
